Inflammatory bowel disease (IBD) is a chronic condition that leads to significant morbidity and decreased quality of life (QOL).^{1, 2} Biologic therapies remain the most effective treatments for those with moderate-to-severe IBD, as they can alter the disease course and achieve sustained mucosal healing, leading to symptom remission, fewer hospitalizations, and improved QOL.^3-6 As of March 2017, seven biologics are approved for use in IBD – adalimumab, certolizumab pegol, golimumab, infliximab, natalizumab, ustekinumab, and vedolizumab – and additional therapies are in the pipeline.^{7, 8}